#1 Clinical Trials Search in Europe

Potassium Canrenoate

Potassium Canrenoate, a mineralocorticoid receptor antagonist, is being studied in clinical trials for its potential benefits in treating COVID-19-related complications and improving outcomes in organ donation. This article explores the ongoing research into this drug’s efficacy and safety in these critical medical areas.

Table of Contents

What is Potassium Canrenoate?

Potassium Canrenoate, also known as Canrenone or Canrenoate potassium, is a medication that belongs to a class of drugs called mineralocorticoid receptor antagonists[1]. It is an intravenous form of spironolactone, which is a more commonly known oral medication[2]. Potassium Canrenoate is being studied for its potential benefits in treating various medical conditions.

Conditions Treated with Potassium Canrenoate

Research is ongoing to evaluate the effectiveness of Potassium Canrenoate in treating several conditions, including:

  • COVID-19 Acute Respiratory Distress Syndrome (ARDS): This is a severe lung condition that can occur in patients with COVID-19, causing difficulty breathing[1].
  • COVID-19 Pneumonia: An infection that inflames the air sacs in the lungs, which may fill with fluid or pus, causing cough and difficulty breathing[2].
  • Pulmonary Fibrosis associated with COVID-19: A condition where lung tissue becomes scarred, making it difficult to breathe[2].
  • Organ Transplantation: Potassium Canrenoate is being studied for its potential to improve outcomes in organ transplantation, particularly in kidney transplants from brain-dead donors[3].

How Potassium Canrenoate Works

Potassium Canrenoate works by blocking a receptor in the body called the mineralocorticoid receptor[1]. This receptor is involved in regulating salt and water balance in the body. By blocking this receptor, Potassium Canrenoate may help:

  • Reduce inflammation in the lungs[2]
  • Prevent or reduce pulmonary fibrosis (scarring of the lungs)[2]
  • Protect organs from damage during transplantation procedures[3]

How Potassium Canrenoate is Administered

Potassium Canrenoate is typically administered intravenously (through a vein). The dosage and duration of treatment may vary depending on the condition being treated and the specific research protocol. For example:

  • In COVID-19 ARDS studies, it may be given for 7 days in addition to standard treatments[1].
  • In studies on COVID-19 pneumonia, it may be administered as 200 mg dissolved in 100 ml of saline solution, given twice a day for 7 days[2].
  • In organ transplantation studies, a single dose of 200 mg may be given to brain-dead donors before organ removal[3].

Ongoing Research and Potential Benefits

Researchers are currently studying Potassium Canrenoate to determine its effectiveness in various conditions. Some potential benefits being investigated include:

  • Reducing the need for mechanical ventilation in COVID-19 patients[1][2]
  • Shortening hospital stays for COVID-19 patients[2]
  • Improving lung function and reducing lung damage in COVID-19 patients[2]
  • Enhancing the survival and function of transplanted kidneys[3]

Potential Side Effects and Monitoring

As with any medication, Potassium Canrenoate may have side effects. Researchers are carefully monitoring patients for potential adverse effects, including:

  • Hypotension: Low blood pressure, defined as systolic blood pressure constantly below 90 mmHg and diastolic blood pressure constantly below 60 mmHg[1]
  • Hyperkalemia: High levels of potassium in the blood, defined as potassium levels above 5.1 mEq/L[1]
  • Renal failure: Kidney problems, monitored by measuring the estimated glomerular filtration rate (eGFR)[1]

Patients receiving Potassium Canrenoate in clinical trials are closely monitored for these and other potential side effects. Blood tests and other assessments are regularly performed to ensure patient safety[1][2][3].

Aspect Details
Drug Name Potassium Canrenoate (also known as Canrenone)
Type of Drug Mineralocorticoid Receptor Antagonist
Main Areas of Study 1. COVID-19 related ARDS and pulmonary fibrosis
2. Organ donation (particularly kidney transplantation)
Administration Method Intravenous (IV)
Key Outcomes Measured 1. Mortality rates
2. Need for mechanical ventilation
3. Duration of hospitalization
4. Changes in inflammatory markers
5. Lung function parameters
6. Kidney graft survival and function
Potential Benefits 1. Improved outcomes in COVID-19 patients with ARDS
2. Prevention of pulmonary fibrosis in COVID-19
3. Enhanced stability in brain-dead organ donors
4. Improved quality and survival of transplanted organs
Monitored Side Effects 1. Hypotension
2. Hyperkalemia
3. Renal failure

FAQ

  • What is Potassium Canrenoate being studied for in COVID-19 patients? Potassium Canrenoate is being investigated as an add-on therapy for moderate to severe Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. It's also being studied for its potential in preventing pulmonary fibrosis associated with COVID-19 infection.
  • How is Potassium Canrenoate administered in these trials? In the COVID-19 trials, Potassium Canrenoate is administered intravenously. The dosage and frequency may vary depending on the specific trial and the patient's condition, particularly their serum potassium levels.
  • What are the potential benefits of using Potassium Canrenoate in organ donation? Potassium Canrenoate is being studied in brain-dead organ donors to assess its impact on hemodynamic stability and potentially improve the quality of harvested organs, particularly kidneys. The goal is to mitigate ischemia-reperfusion injury and enhance graft survival.
  • What are some of the outcomes being measured in these trials? The trials are measuring various outcomes, including mortality rates, need for mechanical ventilation, duration of hospitalization, changes in inflammatory markers, lung function parameters, and in the case of organ donation, the survival and function of transplanted kidneys.
  • Are there any known side effects of Potassium Canrenoate being monitored in these trials? The trials are monitoring for potential side effects such as hypotension (low blood pressure), hyperkalemia (high potassium levels in the blood), and renal failure. These are being carefully tracked to ensure patient safety throughout the studies.

Ongoing Clinical Trials on Potassium Canrenoate

  • A Study Testing Drug Combination for Heart Failure in Women Comparing Increased Doses to Standard Care

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • Study of Drug Combination with Amodiaquine and Potassium Canrenoate Plus Exenatide or Glibenclamide for Patients with Acute Ischemic Stroke

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Greece

Glossary

  • Acute Respiratory Distress Syndrome (ARDS): A serious lung condition that causes fluid to build up in the air sacs, making it difficult to breathe. It's a common complication in severe COVID-19 cases.
  • Mineralocorticoid Receptor Antagonist: A type of medication that blocks the effects of certain hormones on the body, particularly those involved in regulating blood pressure and fluid balance.
  • Pulmonary Fibrosis: A condition where lung tissue becomes scarred and damaged, making it harder for the lungs to work properly. It can be a long-term complication of severe COVID-19.
  • Hemodynamic Stability: The stable and balanced state of blood flow throughout the body, important for maintaining organ function.
  • Ischemia-Reperfusion Injury: Tissue damage caused when blood supply returns to tissue after a period of lack of oxygen. This is a concern in organ transplantation.
  • Brain-dead Organ Donors: Individuals who have been declared brain dead but whose bodies are maintained on life support for the purpose of organ donation.
  • Glomerular Filtration Rate (GFR): A measure of how well the kidneys are filtering waste from the blood, used to assess kidney function.
  • Hyperkalemia: An elevated level of potassium in the blood, which can be a side effect of certain medications and can affect heart function.
  • Intubation: The process of inserting a tube through the mouth and into the airway to help a patient breathe, often used in severe respiratory conditions.
  • Cytokines: Small proteins released by cells that have a specific effect on the interactions and communications between cells, particularly in immune responses.

References

  1. https://clinicaltrials.gov/study/NCT04977960
  2. https://clinicaltrials.gov/study/NCT04912011
  3. https://clinicaltrials.eu/trial/study-on-the-effects-of-potassium-canrenoate-and-trometamol-on-blood-flow-in-brain-dead-organ-donors/